Mass spectrometry reveals potential of β-lactams as SARS-CoV-2 Mpro inhibitors

Tika R. Malla; Anthony Tumber; Tobias John; Lennart Brewitz; Claire Strain-Damerell; C David Owen; Petra Lukacik; H. T. Henry Chan; Pratheesh Maheswaran; Eidarus Salah; Fernanda Duarte; Haitao Yang; Zihe Rao; Martin A. Walsh; Christopher J. Schofield

doi:10.1039/D0CC06870E

This website uses cookies to give you the best user experience. If you continue without changing your settings we'll assume you are happy to receive all RSC cookies. You can change your cookie settings by navigating to our Privacy and Cookies page and following the instructions. These instructions are also obtainable from the privacy link at the bottom of any RSC page.

Lite Version|Standard version

Home > Chemical Communications > Mass spectrometry revea...

Mass spectrometry reveals potential of β-lactams as SARS-CoV-2 M^pro inhibitors

Tika R. Malla, Anthony Tumber, Tobias John, Lennart Brewitz, Claire Strain-Damerell, C David Owen, Petra Lukacik, H. T. Henry Chan, Pratheesh Maheswaran, Eidarus Salah, Fernanda Duarte, Haitao Yang, Zihe Rao, Martin A. Walsh and Christopher J. Schofield
Chem. Commun., 2021,57, 1430-1433
DOI: 10.1039/D0CC06870E, Communication

Open Access Learn more..

This article is licensed under a Creative Commons Attribution 3.0 Unported Licence.

Download

PDF

Rich HTML

Abstract | Cited by

The main viral protease (M^pro) of SARS-CoV-2 is a nucleophilic cysteine hydrolase and a current target for anti-viral chemotherapy. We describe a high-throughput solid phase extraction coupled to mass spectrometry M^pro assay. The results reveal some β-lactams, including penicillin esters, are active site reacting M^pro inhibitors, thus highlighting the potential of acylating agents for M^pro inhibition.

Graphical abstract: Mass spectrometry reveals potential of β-lactams as SARS-CoV-2 Mpro inhibitors

Page: ^ Top

Terms & Conditions | Privacy and Cookies